Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 13144Neoplasms 10492Carcinoma, Non-Small-Cell Lung 6878Prostatic Neoplasms 6276Colorectal Neoplasms 5950Lung Neoplasms 5110Multiple Myeloma 3579Pancreatic Neoplasms 3564Leukemia, Myeloid, Acute 3512Neoplasm Metastasis 3511Carcinoma, Hepatocellular 3277Ovarian Neoplasms 3173Melanoma 3142Stomach Neoplasms 3058Lymphoma 2984Head and Neck Neoplasms 2608Recurrence 2557Precursor Cell Lymphoblastic Leukemia-Lymphoma 2500Leukemia 2362Colonic Neoplasms 2328Brain Neoplasms 2317Lymphoma, Non-Hodgkin 2269Uterine Cervical Neoplasms 2193Rectal Neoplasms 2192Glioblastoma 2018Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1915Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1851Esophageal Neoplasms 1801

Interventions

trifluridine tipiracil drug combination 1Nivolumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite-stable Colorectal Cancer × Clear all
NCT07011550 2026-03-20

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Suspended
7 enrolled
Gastrointestinal

Microsatellite-stable Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡